Navigation Links
Bioniche Pharma and Synerx Pharma Launch Melphalan Hydrochloride for Injection

Launch represents first available generic equivalent of Alkeran(R)

LAKE FOREST, Ill., and NEWTOWN, Pa., June 9 /PRNewswire/ -- Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, and Synerx Pharma, LLC, announced today the FDA approval and launch of Melphalan Hydrochloride for Injection, the generic equivalent of Alkeran(R) from GlaxoSmithKline.


Bioniche Pharma and Synerx Pharma entered into a definitive agreement whereby Synerx developed and secured the U.S. Food and Drug Administration's approval of Melphalan and Bioniche Pharma has the exclusive rights to market and distribute Melphalan in the United States.

"The launch of Melphalan represents Bioniche's introduction to the generic injectable oncology market and underscores our commitment to rapid and aggressive product line growth," said George Zorich, President, US Operations for Bioniche Pharma. "We are pleased to have partnered with Synerx and value their expertise in developing this specialty generic product to meet the needs of cancer patients."

Bioniche Pharma will commence shipment of Melphalan Hydrochloride for Injection immediately in cartons with one single-use vial containing melphalan hydrochloride equivalent to 50 mg melphalan and one 10 mL vial of sterile diluent.

About Bioniche Pharma:

Bioniche Pharma is a global manufacturer of injectable pharmaceutical products serving a variety of niche markets, with expertise in injectable hyaluronic acid products for use in orthopedics, rheumatology, urology and dermatology. The company's growth is fueled by an internal development pipeline and an aggressive acquisition strategy for products. Bioniche Pharma was acquired in February 2006 by RoundTable Healthcare Partners, a private equity firm based in Lake Forest, Illinois. More information about Bioniche Pharma can be found at

About Synerx Pharma:

Synerx Pharma, LLC is a privately help corporation located in historic Bucks County Pennsylvania. Established in January 2004, the company develops and brings to market select pharmaceutical products aimed at addressing unmet market needs, particularly those involving some combination of barriers to entry. The company focuses on developing cost effective specialty generic pharmaceuticals and small brand products. Synerx presently has five FDA approved products, and a development portfolio of ten projects at various stages of development in multiple dosage forms. More information can be found at

Alkeran(R) is a registered trademark of GlaxoSmithKline.

SOURCE Bioniche Pharma
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Bioniche Represented at House of Commons Sub-Committee on Food Safety
2. Bioniche Phase III Clinical Trial with Urocidin(TM) Progressing Well
3. Bioniche Reports Fiscal 2009 Third Quarter
4. Bioniche Provides a Corporate Update
5. Bioniche Completes Recruitment in First Phase III Clinical Trial with Urocidin(TM)
6. Bioniche Revolving Credit Facility Maturity Date Amended
7. Bioniche Phase II Bladder Cancer Trial Results Published in The Journal of Urology
8. Bioniche Warrants Expiration Date to be Extended
9. Bioniche Reports Fiscal 2009 Second Quarter
10. Bioniche Invited to Participate in Canadian Beef Value Chain Roundtable
11. Bioniche Named One of the Top 50 Best Small and Medium Employers in Canada
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June ... , brings up a new, often overlooked aspect of head lice: the parasite’s ability to ... is not a common occurrence, but a necessary one in the event that lice have ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Research and ... Market for Companion Diagnostic Tests" report to their offering. ... for Companion Diagnostics The World Market for ... personalized medicine diagnostics. Market analysis in the report includes the ... Market (In Vitro Diagnostic Kits) by Region (N. America, EU, ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced today ... its e-clinical software solution of choice.  This latest ... possible value to their clients by offering a ... preferred relationship establishes nowEDC as the EDC platform ... MedSource,s full-service clients.  "nowEDC has long been a ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
Breaking Medicine Technology: